Indivior PLC (INDV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Indivior PLC (INDV) has a cash flow conversion efficiency ratio of -0.612x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX158.00 Million ≈ $19.22K USD) by net assets (GBX-258.00 Million ≈ $-31.39K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Indivior PLC net asset quality index to measure how much of total assets are equity-financed.
Indivior PLC - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Indivior PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check INDV cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Indivior PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Indivior PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VIRINCHI ORD (BSE)
NSE:VIRINCHI
|
0.014x |
|
Smithson Investment Trust PLC
LSE:SSON
|
0.000x |
|
Vaswani Industries Limited
NSE:VASWANI
|
0.072x |
|
Fredonia Mining Inc
V:FRED
|
0.640x |
|
Initiator Pharma A/S
ST:INIT
|
-0.144x |
|
FACILITIES BY ADF LS-01
F:ZC8
|
N/A |
|
Assura PLC
LSE:AGR
|
0.042x |
|
Marti Otel Isletmeleri AS
IS:MARTI
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Indivior PLC (2011–2024)
The table below shows the annual cash flow conversion efficiency of Indivior PLC from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Indivior PLC worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX-348.00 Million ≈ $-42.34K |
GBX36.00 Million ≈ $4.38K |
-0.103x | -100.36% |
| 2023-12-31 | GBX-11.00 Million ≈ $-1.34K |
GBX-315.00 Million ≈ $-38.33K |
28.636x | +36611.36% |
| 2022-12-31 | GBX51.00 Million ≈ $6.21K |
GBX-4.00 Million ≈ $-486.68 |
-0.078x | -104.51% |
| 2021-12-31 | GBX203.00 Million ≈ $24.70K |
GBX353.00 Million ≈ $42.95K |
1.739x | +173.88% |
| 2020-12-31 | GBX82.00 Million ≈ $9.98K |
GBX-193.00 Million ≈ $-23.48K |
-2.354x | -425.77% |
| 2019-12-31 | GBX209.00 Million ≈ $25.43K |
GBX151.00 Million ≈ $18.37K |
0.722x | -84.26% |
| 2018-12-31 | GBX66.00 Million ≈ $8.03K |
GBX303.00 Million ≈ $36.87K |
4.591x | +415.92% |
| 2017-12-31 | GBX-203.00 Million ≈ $-24.70K |
GBX295.00 Million ≈ $35.89K |
-1.453x | -5.33% |
| 2016-12-31 | GBX-295.00 Million ≈ $-35.89K |
GBX407.00 Million ≈ $49.52K |
-1.380x | -20.29% |
| 2015-12-31 | GBX-279.00 Million ≈ $-33.95K |
GBX320.00 Million ≈ $38.93K |
-1.147x | -23.82% |
| 2014-12-31 | GBX-475.00 Million ≈ $-57.79K |
GBX440.00 Million ≈ $53.54K |
-0.926x | +92.27% |
| 2013-12-31 | GBX-66.00 Million ≈ $-8.03K |
GBX791.00 Million ≈ $96.24K |
-11.985x | -300.67% |
| 2012-12-31 | GBX145.00 Million ≈ $17.64K |
GBX866.00 Million ≈ $105.37K |
5.972x | +112.17% |
| 2011-12-31 | GBX254.00 Million ≈ $30.90K |
GBX715.00 Million ≈ $86.99K |
2.815x | -- |
About Indivior PLC
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more